Licensing analysis: Chinese deals abound
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
BioNTech's patritumab me-too advances
The company's partner MediLink will start a pivotal trial of beruzatatug pelitecan in lung cancer.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
Amgen takes Imdelltra front line
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
